Business Description
Trevi Therapeutics is a clinical-stage drug development company focused on treating persistent coughing in patients with serious lung conditions, including idiopathic pulmonary fibrosis and other related diseases. Its lead drug candidate, Haduvio, is a slow-release oral pill currently being tested in multiple clinical trials. The company holds a licensing agreement with Keenova Therapeutics to develop and sell medicines based on the active ingredient nalbuphine hydrochloride. Founded in 2011, Trevi Therapeutics operates out of New Haven, Connecticut.
